Patents Assigned to Adienne S.A.
  • Quantitative cellular method for determining the biological activity of an anti-CD26 ligand
    Patent number: 11959913
    Abstract: The present invention relates to a quantitative cellular method for the in vitro determination of the effect of an anti-CD26 ligand, preferably of an anti-CD26 monoclonal antibody, such as begelomab.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: April 16, 2024
    Assignee: ADIENNE S.A.
    Inventor: Antonio Francesco Di Naro
  • ANTI-CD26 ANTIBODIES AND USES THEREOF
    Publication number: 20230383006
    Abstract: The present invention pertains to novel antibodies capable of binding to CD26, as well as to their use as a medicament. Moreover, the present invention provides antibodies for use in treating and/or preventing Graft-versus-Host Disease (GvHD), for use in treating Aplastic Anemia and/or for use in promoting engraftment after haematopoietic stem cell transplantation. Furthermore, the present invention provides pharmaceutical compositions comprising at least one antibody of the present invention, as well as provides a kit of parts.
    Type: Application
    Filed: September 16, 2022
    Publication date: November 30, 2023
    Applicant: ADIENNE S.A.
    Inventor: Antonio Francesco DI NARO
  • TREATMENT OF IDIOPATHIC INFLAMMATORY MYOPATHIES
    Publication number: 20230295328
    Abstract: The invention provides a method of treating an idiopathic inflammatory myopathy in a human patient by administering an anti-CD26 antibody.
    Type: Application
    Filed: July 28, 2020
    Publication date: September 21, 2023
    Applicant: ADIENNE S.A.
    Inventor: Antonio Francesco DI NARO
  • Anti-CD26 antibodies
    Patent number: 11242399
    Abstract: The present invention pertains to novel antibodies capable of binding to CD26, as well as to their use as a medicament. Moreover, the present invention provides antibodies for use in treating and/or preventing Graft-versus-Host Disease (GvHD), for use in treating Aplastic Anemia and/or for use in promoting engraftment after haematopoietic stem cell transplantation. Furthermore, the present invention provides pharmaceutical compositions comprising at least one antibody of the present invention, as well as provides a kit of parts.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: February 8, 2022
    Assignee: ADIENNE S.A.
    Inventor: Antonio Francesco Di Naro
  • QUANTITATIVE CELLULAR METHOD FOR DETERMINING THE BIOLOGICAL ACTIVITY OF AN ANTI-CD26 LIGAND
    Publication number: 20200319169
    Abstract: The present invention relates to a quantitative cellular method for the in vitro determination of the effect of an anti-CD26 ligand, preferably of an anti-CD26 monoclonal antibody, such as begelomab.
    Type: Application
    Filed: December 21, 2018
    Publication date: October 8, 2020
    Applicant: ADIENNE S.A.
    Inventor: Antonio Francesco DI NARO
  • Anti-CD26 antibodies and uses thereof
    Patent number: 9376498
    Abstract: The present invention pertains to novel antibodies capable of binding to CD26, as well as to their use as a medicament. Moreover, the present invention provides antibodies for use in treating and/or preventing Graft-versus-Host Disease (GvHD), for use in treating Aplastic Anemia and/or for use in promoting engraftment after haematopoietic stem cell transplantation. Furthermore, the present invention provides pharmaceutical compositions comprising at least one antibody of the present invention, as well as provides a kit of parts.
    Type: Grant
    Filed: February 19, 2014
    Date of Patent: June 28, 2016
    Assignee: ADIENNE S.A.
    Inventor: Antonio Francesco Di Naro
  • Anti-C5 alpha antibodies
    Patent number: 8962819
    Abstract: The present invention refers to recombinant antibodies of human origin specific for the C5 component of the activated complement and characterised by the ability to inhibit the conversion of the C5 alpha chain to C5a and C5b. Moreover the present invention refers to the nucleotide sequences coding for such antibodies and to the therapeutic use of both polypeptide and nucleotide sequences, in particular for the therapy of diseases involving tissue damage deriving from uncontrolled activation of the complement system.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: February 24, 2015
    Assignee: Adienne S.A.
    Inventors: Francesco Tedesco, Roberto Marzari